Abstract
Two patients who underwent autologous bone marrow transplantation for recurrent non-Hodgkin's lymphoma relapsed at 46 and 28 days after the transplant. Both patients had an HLA-identical sibling and were treated with high-dose chemotherapy and allogeneic marrow transplantation. One patient is now 24 months after the allogeneic transplant without evidence of disease. The second patient died on day 7 with interstitial pneumonia. We conclude that high-dose therapy and allogeneic bone marrow transplantation after failure of autologous transplantation for non-Hodgkin's lymphoma is feasible and should be considered in young patients with HLA-identical siblings.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bleomycin / administration & dosage
-
Bone Marrow Transplantation*
-
Burkitt Lymphoma / drug therapy
-
Burkitt Lymphoma / surgery*
-
Cisplatin / administration & dosage
-
Combined Modality Therapy
-
Cyclophosphamide / administration & dosage
-
Cytarabine / administration & dosage
-
Dexamethasone / administration & dosage
-
Doxorubicin / administration & dosage
-
Humans
-
Leucovorin / administration & dosage
-
Lymphoma, Non-Hodgkin / drug therapy
-
Lymphoma, Non-Hodgkin / surgery*
-
Male
-
Methotrexate / administration & dosage
-
Prednisone / administration & dosage
-
Reoperation
-
Transplantation, Autologous
-
Transplantation, Homologous
-
Vincristine / administration & dosage
Substances
-
Cytarabine
-
Bleomycin
-
Vincristine
-
Dexamethasone
-
Doxorubicin
-
Cyclophosphamide
-
Cisplatin
-
Leucovorin
-
Prednisone
-
Methotrexate
Supplementary concepts
-
COMLA protocol
-
COMP protocol
-
DHAP protocol
-
M-BACOD protocol